Ifosfamide
- Generic Name
- Ifosfamide
- Brand Names
- Ifex
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 3778-73-2
- Unique Ingredient Identifier
- UM20QQM95Y
- Background
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
- Indication
Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
- Associated Conditions
- Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
- Associated Therapies
- -
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
- Conditions
- Interventions
- Biological: bleomycin sulfateDrug: ABVD regimenDrug: cisplatinDrug: carmustineDrug: cytarabineDrug: dacarbazineDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: gemcitabine hydrochlorideDrug: methylprednisoloneDrug: vincristine sulfateDrug: ifosfamideDrug: vindesineDrug: melphalanDrug: mitoguazoneDrug: vinorelbine tartrateProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 442
- Registration Number
- NCT00920153
- Locations
- 🇫🇷
FILO French Innovative Leukemia Organization, Tours Cedex, France
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00880542
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00878254
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis
- Conditions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 101
- Registration Number
- NCT00864318
- Locations
- 🇫🇷
Hopital St André, Bordeaux, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Claudius Regaud, Toulouse, France
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 50
- Registration Number
- NCT00842595
- Locations
- 🇫🇷
Hôpital COCHIN, Paris, France
Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
- Conditions
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Registration Number
- NCT00829205
- Locations
- 🇬🇧
Derriford Hospital, Plymouth, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
🇬🇧Barts and the London NHS Trust, London, England, United Kingdom
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
- Conditions
- Interventions
- Drug: epirubicin hydrochlorideDrug: ifosfamideDrug: sorafenib tosylateOther: immunoenzyme techniqueOther: immunohistochemistry staining methodOther: laboratory biomarker analysisProcedure: adjuvant therapyProcedure: neoadjuvant therapyProcedure: therapeutic conventional surgeryRadiation: hypofractionated radiation therapy
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00822848
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2018-09-25
- Target Recruit Count
- 27
- Registration Number
- NCT00809341
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-12-10
- Target Recruit Count
- 121
- Registration Number
- NCT00796120
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT00788125
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.